CA3068100A1 - Modified l-asparaginase - Google Patents
Modified l-asparaginase Download PDFInfo
- Publication number
- CA3068100A1 CA3068100A1 CA3068100A CA3068100A CA3068100A1 CA 3068100 A1 CA3068100 A1 CA 3068100A1 CA 3068100 A CA3068100 A CA 3068100A CA 3068100 A CA3068100 A CA 3068100A CA 3068100 A1 CA3068100 A1 CA 3068100A1
- Authority
- CA
- Canada
- Prior art keywords
- asparaginase
- modified protein
- amino acid
- peptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
- C12N9/82—Asparaginase (3.5.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
- C12Y305/01001—Asparaginase (3.5.1.1)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523061P | 2017-06-21 | 2017-06-21 | |
| EP17177237.9A EP3418383A1 (en) | 2017-06-21 | 2017-06-21 | Modified l-asparaginase |
| EP17177237.9 | 2017-06-21 | ||
| US62/523,061 | 2017-06-21 | ||
| US15/671,086 | 2017-08-07 | ||
| US15/671,086 US10174302B1 (en) | 2017-06-21 | 2017-08-07 | Modified L-asparaginase |
| PCT/EP2018/066647 WO2018234492A1 (en) | 2017-06-21 | 2018-06-21 | L-ASPARAGINASE MODIFIED |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3068100A1 true CA3068100A1 (en) | 2018-12-27 |
Family
ID=64737515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3068100A Pending CA3068100A1 (en) | 2017-06-21 | 2018-06-21 | Modified l-asparaginase |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3642340B1 (https=) |
| JP (2) | JP7808424B2 (https=) |
| KR (1) | KR102727396B1 (https=) |
| CN (1) | CN111315878B (https=) |
| AU (1) | AU2018287145B2 (https=) |
| BR (1) | BR112019027479A2 (https=) |
| CA (1) | CA3068100A1 (https=) |
| DK (1) | DK3642340T3 (https=) |
| ES (1) | ES2979314T3 (https=) |
| FI (1) | FI3642340T3 (https=) |
| IL (1) | IL271504B2 (https=) |
| MX (2) | MX2019015502A (https=) |
| SA (2) | SA519410870B1 (https=) |
| SG (1) | SG11201912625QA (https=) |
| WO (1) | WO2018234492A1 (https=) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2877539T3 (es) | 2015-12-22 | 2021-11-17 | Xl Protein Gmbh | Acidos nucleicos que codifican secuencias repetitivas de aminoácidos ricos en residuos de prolina y alanina que tienen bajas secuencias de nucleótidos repetitivas |
| IL271504B2 (en) * | 2017-06-21 | 2024-05-01 | Jazz Pharmaceuticals Ireland Ltd | Modified l-asparaginase |
| WO2019101308A1 (en) * | 2017-11-22 | 2019-05-31 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
| US20220227805A1 (en) * | 2020-12-23 | 2022-07-21 | Jazz Pharmaceuticals Ireland Ltd. | Methods of purifying charge-shielded fusion proteins |
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8519753D0 (en) * | 1985-08-06 | 1985-09-11 | Health Lab Service Board | Production of 1-asparaginase |
| GB9017002D0 (en) * | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US7985548B2 (en) | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| US7666652B2 (en) * | 2007-03-09 | 2010-02-23 | Novozymes A/S | Asparaginases |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| CN117462693A (zh) | 2012-02-27 | 2024-01-30 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| IL271504B2 (en) | 2017-06-21 | 2024-05-01 | Jazz Pharmaceuticals Ireland Ltd | Modified l-asparaginase |
-
2018
- 2018-06-21 IL IL271504A patent/IL271504B2/en unknown
- 2018-06-21 EP EP18731853.0A patent/EP3642340B1/en active Active
- 2018-06-21 BR BR112019027479-0A patent/BR112019027479A2/pt unknown
- 2018-06-21 DK DK18731853.0T patent/DK3642340T3/da active
- 2018-06-21 JP JP2019571042A patent/JP7808424B2/ja active Active
- 2018-06-21 EP EP22204187.3A patent/EP4180525A1/en active Pending
- 2018-06-21 CA CA3068100A patent/CA3068100A1/en active Pending
- 2018-06-21 AU AU2018287145A patent/AU2018287145B2/en active Active
- 2018-06-21 SG SG11201912625QA patent/SG11201912625QA/en unknown
- 2018-06-21 CN CN201880054251.4A patent/CN111315878B/zh active Active
- 2018-06-21 KR KR1020207002029A patent/KR102727396B1/ko active Active
- 2018-06-21 MX MX2019015502A patent/MX2019015502A/es unknown
- 2018-06-21 WO PCT/EP2018/066647 patent/WO2018234492A1/en not_active Ceased
- 2018-06-21 FI FIEP18731853.0T patent/FI3642340T3/fi active
- 2018-06-21 ES ES18731853T patent/ES2979314T3/es active Active
-
2019
- 2019-12-18 MX MX2024015050A patent/MX2024015050A/es unknown
- 2019-12-21 SA SA519410870A patent/SA519410870B1/ar unknown
- 2019-12-21 SA SA522433360A patent/SA522433360B1/ar unknown
-
2023
- 2023-02-28 JP JP2023030460A patent/JP7770352B2/ja active Active
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12128021B1 (en) | 2016-07-22 | 2024-10-29 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11766418B2 (en) | 2016-07-22 | 2023-09-26 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263151B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11826335B2 (en) | 2016-07-22 | 2023-11-28 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11839597B2 (en) | 2016-07-22 | 2023-12-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11896572B2 (en) | 2016-07-22 | 2024-02-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097176B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12097175B2 (en) | 2016-07-22 | 2024-09-24 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12109186B2 (en) | 2016-07-22 | 2024-10-08 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115142B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115144B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115143B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12115145B2 (en) | 2016-07-22 | 2024-10-15 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12239625B2 (en) | 2016-07-22 | 2025-03-04 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12138239B2 (en) | 2016-07-22 | 2024-11-12 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12144793B2 (en) | 2016-07-22 | 2024-11-19 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12263150B2 (en) | 2016-07-22 | 2025-04-01 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12257223B2 (en) | 2016-07-22 | 2025-03-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186298B2 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226389B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12226388B2 (en) | 2016-07-22 | 2025-02-18 | Flamel Ireland Limited | Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics |
| US12226377B2 (en) | 2019-03-01 | 2025-02-18 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167992B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12167991B2 (en) | 2019-03-01 | 2024-12-17 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US12303478B2 (en) | 2019-03-01 | 2025-05-20 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12295926B1 (en) | 2022-02-07 | 2025-05-13 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US12551457B1 (en) | 2022-02-07 | 2026-02-17 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111315878A (zh) | 2020-06-19 |
| EP4180525A1 (en) | 2023-05-17 |
| SA522433360B1 (ar) | 2024-06-23 |
| ES2979314T3 (es) | 2024-09-25 |
| JP7808424B2 (ja) | 2026-01-29 |
| RU2020101972A (ru) | 2021-07-21 |
| AU2018287145B2 (en) | 2024-04-18 |
| JP2020528743A (ja) | 2020-10-01 |
| RU2020101972A3 (https=) | 2021-11-09 |
| WO2018234492A1 (en) | 2018-12-27 |
| EP3642340B1 (en) | 2024-03-20 |
| JP7770352B2 (ja) | 2025-11-14 |
| KR20200030065A (ko) | 2020-03-19 |
| SG11201912625QA (en) | 2020-01-30 |
| IL271504B1 (en) | 2024-01-01 |
| KR102727396B1 (ko) | 2024-11-08 |
| MX2019015502A (es) | 2020-07-28 |
| SA519410870B1 (ar) | 2023-03-06 |
| AU2018287145A1 (en) | 2020-02-06 |
| FI3642340T3 (fi) | 2024-06-18 |
| DK3642340T3 (da) | 2024-06-03 |
| IL271504B2 (en) | 2024-05-01 |
| CN111315878B (zh) | 2024-04-26 |
| JP2023081915A (ja) | 2023-06-13 |
| EP3642340A1 (en) | 2020-04-29 |
| IL271504A (en) | 2020-02-27 |
| MX2024015050A (es) | 2025-01-09 |
| BR112019027479A2 (pt) | 2020-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240076643A1 (en) | Modified l-asparaginase | |
| JP7770352B2 (ja) | 修飾されたｌ－アスパラギナーゼ | |
| EP3418383A1 (en) | Modified l-asparaginase | |
| USRE49736E1 (en) | Pegylated L-asparaginase | |
| Wu et al. | Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone | |
| EP2451486B1 (en) | Pegylated l-asparaginase | |
| EP4015526A1 (en) | Recombinant interleukin-15 analog | |
| WO2021074683A1 (en) | Bispecific anti-pd-l1 and anti-fcrn polypeptides | |
| KR20120137364A (ko) | Ｉｇｆ―ⅰ 폴리(에틸렌 글리콜) 컨쥬게이트 | |
| HK40090811A (en) | Modified l-asparaginase | |
| RU2775696C2 (ru) | Модифицированная l-аспарагиназа | |
| HK40029594B (en) | Modified l-asparaginase | |
| HK40029594A (en) | Modified l-asparaginase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220629 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241023 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250221 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250303 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250523 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250523 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250708 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250708 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260316 |